@Soprano The company has a large pipeline, so not just the one drug. I took a look at the estimates. Earnings per share go up from 4.39 to 7.48. Free cash flow from 9397.86 to 10433.23 EbiT margin from 29 to 43 Turnover continues to rise. The P/E ratio falls to 13
